Item 7.01 Regulation FD Disclosure. On February 24, 2025, the Company issued a press release announcing that the U. S. Food and Drug Administration (FDA) has completed its review of Phase 1 data and Investigational New Drug (IND) application submitted by DeFloria, Inc. (“ DeFloria”), an entity of which the Company holds a minority interest. DeFloria can now proceed with its planned Phase 2 clinical trial for its botanical pharmaceutical candidate, AJA001 Oral Solution, a treatment for symptoms of autism spectrum disorder. A copy of the press release is filed as Exhibit 99.1 and incorporated into this Item 7.01 by reference. The information in this Item 7.01 of this Form 8-K is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit Description No. 99.1 Press Release dated February 24, 2025 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data File (embedded within the Inline XBRL document The information in the press release attached SIGNATURES